Navigation Links
Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
Date:3/20/2008

SEATTLE, March 20 /PRNewswire/ -- Fred Hutchinson Cancer Research Center (FHCRC) and NSB POSTECH, Inc. (NSB) have reached a collaboration agreement to coordinate their efforts and to determine the efficacy of the NSB's NanoCones surface technology in creating high quality proteomic microarrays to be used in the study of human diseases.

NSB is a South Korean biotech company which possesses a proprietary microarray technology and a great deal of expertise in nano-scale controlled surface chemistry. NSB has agreed to fund the collaboration.

Announced today, this collaboration will involve a comparison of slides created with NSB's newly developed NanoCones surface technology and the current industry standard.

"This is the first time a Korean biotech company has had an opportunity to collaborate with a major U.S.-based cancer research center. We are very thrilled to be working with scientists at the Hutchinson Center," said Dr. Joon Won Park, president of NSB and one of the inventors of the NanoCones technology.

"We are excited about the preliminary data that has been generated when antibodies were arrayed using the NanoCones technology. We hope this will make our antibody arrays more sensitive and accurate," said Dr. Paul Lampe, member of the Hutchinson Center's Public Health Sciences Division and associate program head of molecular diagnostics.

Antibody or protein microarrays are glass microscope slides onto which very small amounts of thousands of different antibodies or proteins have been affixed at distinct locations. Antibody microarrays can be used to simultaneously determine the level of each antibody's specific binding partner in complex mixtures such as blood so thousands of different assays can be performed with small amounts of sample.

At Fred Hutchinson Cancer Research Center, interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Hutchinson Center researchers, including three Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, visit http://www.fhcrc.org.

NSB POSTECH, Inc. is a South Korea based Biotech Company specializing in nano-surface technology for genomic and proteomic microarrays. NSB's mission is to detect and prevent disease. NanoCones technology research was funded with support from POSCO, Korea's world-renowned steel manufacturer and POSTECH, one of Asia's leading Science and Technology Universities. For more information, visit http://www.nsbpostech.com.


'/>"/>
SOURCE NSB POSTECH, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin is joining ... She brings years of expertise in establishing and leading clinical operations at Sponsors ... licensed occupational therapist, through a variety of leadership roles in Clinical Operations, to ...
(Date:5/22/2017)... , ... May 22, 2017 , ... ... with other leaders of the Maryland Biohealth community in developing and issuing recommendations ... Top 3 U.S. BioHealth Innovation Hub by 2023. , The ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science Center ... ripe for commercialization, and who are affiliated with the 21 partner academic and ... QED, now in its tenth round, is the first multi-institutional proof-of-concept program for ...
(Date:5/18/2017)... ... 17, 2017 , ... DAACRO ... power by providing investigators access to a high-profile scientific advisory board. Today, ... advisory board. “We are committed to offering superior services and solutions for ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
Breaking Biology News(10 mins):